Immutep Limited is an Australia-based biotechnology company. The Company is engaged in the development of LAG-3 immunotherapeutic products, an immunotherapy for cancer and autoimmune disease. The Company has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761), which is in pre-clinical development for the treatment of autoimmune disease. The Companyâ€™s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSKâ€˜781). The Companyâ€™s operates through its subsidiaries, which include Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S..